The promising new innovations from companies in Western Australia, South Australia, Victoria and New South Wales include an early test for deep vein thrombosis, a new approach to heart valve replacement, an AI-software platform for analysis of arterial disease, a pulse sensing device to improve CPR, and paediatric vascular access technology for critical care.
AUScelerate CEO Stuart Dignam says the funding is the latest to flow from the organisation’s Targeted Translation Research Accelerator, supported by the Medical Research Future Fund.
“At a time when accessing non-dilutive capital is particularly tough, we are delighted to back these companies with much-needed non-dilutive funding and expert commercialisation support to continue the translation of their innovations on Australian soil,” Mr Dignam said.
“World Heart Day is a fitting occasion to recognise both the toll heart disease takes on patients, carers, families and communities and the promise that medtech innovations such as these hold for better health and wellbeing.
“Working with our in-house specialists and industry partners, these companies will tap into local and international expertise giving them the best chances of building sovereign success to reach commercial proof-of-concept.
“It’s about backing Australian innovations to tackle significant chronic health problems and scale in our backyard rather than offshore.
“The diversity of the new cohort is also outstanding, with 60 per cent being female-led projects,” Mr Dignam said.
The Targeted Translation Research Accelerator is delivered by AUScelerate with support from the Medical Research Future Fund and in collaboration with Impact Partners CSL and Roche Diagnostics Australia who bring additional industry knowledge, market expertise and commercialisation experience.
